FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Published Online: Wednesday, December 19, 2012
Follow Pharmacy_Times:
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.
Related Articles
With proper treatment, individuals with atrial fibrillation can live normal and active lives.
Scientists from the Diabetes Research Centre at the University of Leicester have identified a link between low blood glucose levels and adverse cardiovascular events in patients with diabetes.
New research posits that cocaine use quadruples the risk of sudden cardiovascular death among individuals aged 19 to 49 years.
Poor sleep quality and cardiovascular disease often go hand in hand.
Latest Issues
$auto_registration$